Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

The Lancet. Haematology·2026
Same author

Corrigendum to "A meta-analysis of criterion effects for the Implicit Relational Assessment Procedure (IRAP) in the clinical domain" [Journal of Behavior Therapy and Experimental psychiatry 48 (2015) 59-65].

Journal of behavior therapy and experimental psychiatry·2026
Same author

A Virtual Versus In-Person Comparison of the Senior Fitness Test: A Randomized Crossover Trial.

Physiotherapy Canada. Physiotherapie Canada·2026
Same author

Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia.

Leukemia·2026
Same author

Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia - a study on behalf of the Chronic Malignancies Working Party of the EBMT.

Haematologica·2026
Same author

Targeting systemic and tumor metabolic balances with ketogenic diets enhance efficacy of therapy in FLT3-ITD acute myeloid leukemia.

Cell reports·2026

Related Experiment Video

Updated: Jun 17, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Targeted therapy in haematological malignancies.

Ashley Hamilton1, Paolo Gallipoli, Emma Nicholson

  • 1Section of Experimental Haematology, Cancer Division, Faculty of Medicine, University of Glasgow, and Paul O'Gorman Leukaemia Research Centre, Gartnavel General Hospital, Glasgow, UK.

The Journal of Pathology
|December 31, 2009
PubMed
Summary

Molecularly targeted therapies have revolutionized hematological malignancy treatment, improving survival in chronic myeloid leukemia and non-Hodgkin lymphoma. Targeting leukemia stem cells offers new hope for better responses and reduced relapse rates.

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Experiment Videos

Last Updated: Jun 17, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Molecularly targeted therapy has rapidly advanced hematological malignancy management.
  • Significant progress has been made in treating both myeloid and lymphoid malignancies.

Purpose of the Study:

  • To review recent advances in molecularly targeted therapies for hematological malignancies.
  • To highlight the impact of targeted agents on patient survival and quality of life.
  • To discuss the emerging role of targeting leukemia stem cells.

Main Methods:

  • Review of recent clinical trials and therapeutic advancements.
  • Analysis of the impact of specific targeted agents (e.g., kinase inhibitors, ATRA, rituximab).
  • Discussion of preclinical discoveries and their progression to clinical application.

Main Results:

  • ABL and Src/ABL kinase inhibitors have dramatically improved survival in chronic myeloid leukemia.
  • JAK2 inhibitors show promise for myeloproliferative diseases.
  • ATRA and myelotarg have impacted acute myeloid leukemia treatment regimens.
  • Rituximab has significantly improved outcomes in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
  • Targeting leukemia stem cells is a key focus for improving treatment efficacy and reducing relapse.

Conclusions:

  • Molecularly targeted therapies have transformed hematological cancer care.
  • Further development and clinical translation of novel targeted agents, particularly those targeting leukemia stem cells, are anticipated.